The state-of-the-art aortic endograft is designed for thoracic endovascular aortic repair (TEVAR), a minimally invasive alternative to traditional, open surgery. The Zenith TX2 is indicated to treat patients with aneurysms or ulcers of the descending thoracic aorta having vascular morphology suitable for endovascular repair.
Cook’s Zenith TX2 is said to provide the US physicians with an endovascular solution for the interventional treatment of thoracic aortic aneurysms (TAA), including patients who may not be eligible for treatment through open surgery.
Phil Nowell, global director of aortic intervention strategic business unit at Cook, said: “We are thrilled to reach this important milestone and introduce in the US the Zenith TX2 which is uniquely designed to treat a broad range of patients suffering from TAA.”